Trial · NCT07910058
Sacubitril/Valsartan vs Standard Treatment for Preventing Atrial Fibrillation Recurrence After Catheter Ablation in Persistent Atrial Fibrillation Patients With Without Hypertension
NCT07910058, Phase 4, Not yet recruiting, Ruijin Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sacubitril/Valsartan vs Standard Treatment for Preventing Atrial Fibrillation Recurrence After Catheter Ablation in Persistent Atrial Fibrillation Patients With Without Hypertension. Trials, record NCT07910058. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07910058
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sacubitril/Valsartan vs Standard Treatment for Preventing Atrial Fibrillation Recurrence After Catheter Ablation in Persistent Atrial Fibrillation Patients With Without Hypertension
- NCT number
- NCT07910058
- Status
- Not yet recruiting
- Phases
- Phase 4
- Enrollment
- 472 participants, estimated
- Lead sponsor
- Ruijin Hospital
- Conditions
- Atrial Fibrillation (Persistent), Catheter Ablation, Non-hypertension, Angiotensin Receptor/Neprilysin Inhibitor
- Interventions
- Sacubitril/Valsartan, Standard Care
- First posted
- 2026-11-02
- Last updated
- 2026-11-04
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The difference in the proportion of late atrial tachyarrhythmia recurrence between the two treatment groups. | Between 3 and 12 months after catheter ablation. | Late atrial tachyarrhythmia recurrence is defined as any documented episode of atrial fibrillation, atrial flutter, or atrial tachycardia lasting more than 30 seconds, detected by single-lead electrocardiography (ECG), 12-lead ECG, or 24-hour Holter monitoring during the follow-up period from 3 to 12 months. |
| Secondary | The difference in the proportion of early atrial tachyarrhythmia recurrence between the two treatment groups. | From day 2 to 3 months post-ablation | Early recurrent atrial arrhythmia is defined as documented atrial fibrillation, atrial flutter, or atrial tachycardia lasting \>30 seconds detected by ECG or Holter monitoring from day 2 to 3 months post-ablation. |
| Secondary | Changes in office and 24-hour ambulatory blood pressure from baseline to 12 months. | Baseline and 12 months | |
| Secondary | Changes in NT-proBNP from baseline to 12 months. | Baseline and 12 months | |
| Secondary | Changes in left atrial global longitudinal strain from baseline to 12 months. | Baseline and 12 months | Measured by echocardiography |
| Secondary | Changes in atrial fibrosis imaging in the CMR or [68Ga]FAPI-PET-CMR sub-cohort from baseline to 12 months. | Baseline and 12 months | Quantified by late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) or \[68Ga\]FAPI 04-PET/MRI imaging. |
| Secondary | Composite cardiovascular outcomes, including fatal and non-fatal stroke, acute myocardial infarction, and cardiovascular death during 12 months of follow-up. | From randomization up to 12 months | Includes fatal and non-fatal stroke, acute myocardial infarction, and cardiovascular death. |
| Other | Incidence of safety endpoints | From randomization up to 12 months | Incidence of symptomatic hypotension, renal deterioration, hyperkalemia, and angioedema. |
| Other | Exploratory outcomes: Proteomic and metabolomic profile changes from baseline to 12 months to explore mechanisms and biomarkers. | Baseline and 12 months |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07910058
GET https://conductscience.org/api/trials/v1/NCT07910058/registered